Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Oct 16 - Oct 21
AOD-9604 offers a gentler approach with more selective fat targeting and fewer systemic effects, making it suitable for individuals who cannot tolerate GLP-1 agonists or prefer a more focused mechanism
The plan appears to be effective because of the accompanying starvation diet, experts said
Insurance coverage for BPC-157 remains limited in 2026, with most patients paying out-of-pocket for treatment
***p = 0.0005 (hepatocellular carcinoma)
At dispensing, the syringe volume on the patient instructions is checked against the labeled concentration
US$ 21.88
US$ 25.00
US$ 21.15
